Wednesday , October 27 2021

Sun Pharma files application for Tildrakizumab in Japan

Sun Pharmaceutical Industries has filed an application for Manufacturing and Marketing Authorization of Tildrakizumab for moderate-to-severe psoriasis and psoriatic arthritis with the Pharmaceuticals and Medical Devices Agency (PMDA), Japan.

The recent acquisition of Pola Pharma in Japan will help the company leverage Pola’s strong presence in the dermatology segment to commercialize Tildrakizumab post regulatory approval. The company had acquired Pola Pharma in January 2019.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'